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Abstract: 
Introduction: Reduced estimated glomerular filtration rate (eGFR) is associated with increased 
risk of cardiovascular disease among people living with HIV (PLWH).  It is unclear whether 
eGFR equations incorporating Cystatin C (CysC) measurements are more predictive of 
preclinical CVD than those using only creatinine (Cr).  
Objectives: The study aimed to determine which of the three Chronic Kidney Disease 
Epidemiology (CKD-EPI) eGFR equations is most associated with carotid intima media 
thickness (CIMT) and coronary artery calcium (CAC) score.  
Methods: This cross-sectional analysis of pooled data from three large cohorts compared the 
associations between the three CKD-EPI eGFR equations (Cr, CysC, and Cr-CysC) with CIMT 
and CAC score using multivariable regression analysis. eGFR and CIMT were analyzed as 
continuous variables. CAC scores were analyzed as a binary variable (detectable calcification 
versus nondetectable) and as a log10 Agatston score in those with detectable CAC. 
Results: 1487 participants were included, and of these 910 (562 HIV+, 348 HIV-) had CIMT 
measurements and 366 (296 HIV+, 70 HIV-) had CAC measurements available. In HIV- 
participants, GFR estimated by any CKD-EPI equation did not significantly correlate with CIMT 
or CAC scores. When PLWH were analyzed separately including HIV-specific factors, only 
GFR estimated using Cr-Cys C correlated with CIMT [β= -0.90, 95% CI (-1.67,-0.13) µm; 





eGFR [β= -8.63, 95% CI (-16.49,-0.77) HU; p=0.034]. Associations between other eGFR 
formulas and CAC did not reach statistical significance.  
Conclusion:  In PLWH, preclinical atherosclerosis may be more closely correlated with eGFR 
using formulae that incorporate CysC measurements than Cr alone. 
Key words: HIV-1; Cystatin C; Carotid Intima Media Thickness; Coronary Artery Calcium; 
Cardiovascular disease; Glomerular Filtration Rate 
Introduction 
Reduced estimated glomerular filtration rate (eGFR) is associated with an increased risk 
of cardiovascular disease (CVD) in both the general population[1, 2] and people living with HIV 
(PLWH)[3-5]. GFR estimating equations incorporating serum cystatin C, compared to those using 
solely serum creatinine, are more predictive of cardiovascular events and overall mortality in the 
general population[6] and of overall mortality in PLWH[4, 7-10]. We sought to determine whether 
cystatin C-based or creatinine-based estimates of GFR were more strongly associated with two 
measures of subclinical cardiovascular disease, which are predictors of cardiovascular events, 
namely carotid intima media thickness (CIMT) and coronary artery calcium (CAC)[11-17]  
Methods 
We conducted a cross sectional analysis of data pooled from three large observational 
cohorts of PLWH and HIV- uninfected (HIV-) controls [Veterans Aging Cohort Study (VACS), 
Multicenter AIDS Cohort Study (MACS), and Hawaii Aging with HIV-1 Cohort (HA)]. We 





(ultrasound measured at the right distal common carotid artery) and CAC scores measured by CT 
scanning. We performed these analyses using each of three CKD-EPI eGFR equations 
[creatinine (Cr), cystatin C (CysC), and both creatinine and cystatin C (Cr-CysC)][18, 19]. Serum 
CysC was quantified centrally using N Latex Cystatin C kit per manufacturer instructions 
(Seimens, Eschborn, Germany). Our models included the entire pooled cohort and included an 
interaction term between HIV serostatus and eGFR. Covariates in all models included 
demographic factors (age, sex, race/ethnicity) and CVD and kidney disease risk factors (systolic 
and diastolic blood pressure, history of diabetes, total cholesterol, LDL-C, HDL-C, triglycerides, 
smoking status, body mass index, hepatitis C serostatus). We also constructed models in PLWH 
alone and included HIV-specific factors (CD4+ T cell count, HIV-1 RNA level, and history of 
antiretroviral medication use). CIMT, CAC, and CysC were centrally measured as previously 
described[20-22]; serum Cr was measured locally. eGFR and CIMT were analyzed as continuous 
variables. CAC scores were analyzed as a continuous variable using log10Agatston score in 
persons with detectable CAC. Statistical significance was defined as P<0.05. 
Results 
We included 1487 participants (945 HIV+, 542 HIV-). Of these 910 (562 HIV+, 348 
HIV-) and 366 (296 HIV+, 70 HIV-) had CIMT and CAC measurements available, respectively 
(Supplementary Table 1,http://links.lww.com/QAI/B519). Among persons with CIMT 
measurements, 96.3% were male, 22.5% were Black, 11.9% Hispanic, 57.9% White, and 7.7% 
Asian. There were 4.3-5.4% with eGFR <60 mL/min/1.73m2 and 25.1-52.3% had eGFR <90 
mL/min/1.73m2, depending on the eGFR formula used. Mean (SD) CIMT was 0.79 (0.15) mm 





Among persons with CAC measurements, 94% were male, 47% were Black, 9.6% were 
Hispanic, 31.5% were White, and 11.8% were Asian. There were 4.8-5.9% with eGFR <60 
mL/min/1.73m2 and 27-52.8% had eGFR <90 mL/min/1.73m2, depending on the eGFR formula 
used. Of the 366 with CAC measurements, 176 (48.1%) had detectable CAC, with a mean (SD) 
log10Agatston score of 1.87 (0.79) (Supplementary table 1,http://links.lww.com/QAI/B519). 
In the overall cohort including both PLWH and HIV- participants, neither creatinine nor 
cystatin C-based eGFR were associated with greater CIMT (Table 1). Of note, there was an 
interaction between HIV status and Cr based eGFR’s relationship with CIMT (β (95% CI) = -
1.32 (-2.49,-0.15), P=0.027). When PLWH were analyzed separately including HIV-specific 
factors, eGFR using Cr-Cys C model correlated with greater CIMT. In PLWH, each 10 
mL/min/1.73m2 lower in eGFR by Cr-CysC was associated with a 9.0 µm (95% CI, -16.7,-1.3 
µm; P=0.023) greater CIMT. Associations with other eGFR formulas did not reach statistical 
significance.  
Similarly, neither creatinine nor cystatin C based estimates of GFR were associated with 
greater Agatston scores in the cohort regardless of HIV serostatus (Table 2). However, when 
PLWH were analyzed separately including HIV-specific factors, eGFR correlated with higher 
Agatston scores only when using cystatin C-based eGFR. Each 10 mL/min/1.73m2 decrease in 
CysC-eGFR was associated with a 0.086 higher log10Agatston score (95% CI .077, 0.165; 
P=0.034). Associations between other eGFR formulas and CAC did not reach statistical 
significance. None of the GFR estimates were associated with CAC when analyzed as a binary 






In this large and diverse cohort, estimates of GFR that incorporated CysC were more  
significantly correlated with CIMT measurements and Agatston scores in PLWH than GFR 
estimates without CysC. In PLWH, eGFR was inversely correlated to CIMT using Cr-CysC, but 
not with Cr or CysC; eGFR was inversely correlated with CAC Agatston scores using CysC but 
not with Cr or Cr-CysC. This suggests that GFR estimating formulae incorporating cystatin C 
may be more useful to identify PLWH with subclinical CVD who are in greater need of 
aggressive CVD risk reduction. These results are consistent with several studies suggesting that 
cystatin C-based eGFR is more predictive of both CVD and mortality than Cr in PLWH[4, 8, 9, 23]. 
One study reported that CysC eGFR had the strongest association with cardiovascular events of 
the three CKD-EPI equations among PLWH[8]. To date, there has not been a study demonstrated 
that CysC-based eGFR in PLWH is more closely associated with greater CAC or CIMT than Cr-
based eGFR. A recent study using CT angiography found a correlation between Cr-based eGFR 
and calcified coronary plaque and Agatston score in PLWH, but not in HIV- controls[5]. In our 
analysis, creatinine based eGFR did not correlate with higher Agatston scores, but cystatin C 
based eGFR did. This may be explained in part by different methodology of Agatson score 
measurement or differences in study population (their cohort was modestly younger and included 
more women). 
Of note, our analysis did not consistently reveal a link between HIV infection itself and 
greater CIMT or CAC. Similarly, a recent large study suggests that HIV’s association with 
CIMT may be age dependent, with middle-aged patients showing little association between HIV 
and CIMT[24]. Other studies have examined CIMT’s association with HIV and some reported 





subgroups of PLWH [15, 25, 26]. The addition of kidney function estimates in our models may also 
have minimized the relationship between HIV seropositivity and these imaging markers. 
Strengths of our study include having large samples of both PLWH and HIV- participants, use of 
standardized centrally-measured plasma cystatin C, CIMT, and CAC scores, and adjustment for 
other factors known to contribute to development of both renal and cardiovascular disease. 
However, our study is limited by having a predominantly male population with few having an 
eGFR <60 mL/min/1.73m2. We did not have data on antiretroviral, blood pressure, and lipid-
lowering medications, which may have confounding effects on kidney function. Finally, we 
could not assess causality in this cross-sectional analysis.  
In conclusion, investigators studying the interplay between CVD and renal disease in 
PLWH should consider utilizing eGFR formulae that incorporate CysC since these may correlate 
more significantly with atherosclerosis in PLWH.  
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Table 1. Relationships between eGFR (using 3 CKD-EPI equations) and CIMT in HIV-positive and HIV-negative Individuals. 
CIMT 
Cr Model CysC Model Cr-CysC Model 




 HIV status (+/-) 
126.33 (12.95, 
239.72) 
0.029 11.91 (-121.35, 145.16) 0.861 79.78 (-59.37, 
218.93) 
0.262 
   HIV- eGFR 
(mL/min/1.73m2) 
0.74 (-0.27, 1.76) 0.152 -0.40 (-1.47, 0.67) 0.465 0.06 (-1.12,1.24) 0.923 
   HIV+ eGFR 
(mL/min/1.73m2) 
-0.58 (-1.27, 0.11) 0.099 -0.61 (-1.23, 0.01) 0.055 -0.78 (-1.48, -0.08) 0.029 
   HIV*eGFR interaction -1.32 (-2.49, -0.15) 0.027 -0.21 (-1.40, 0.98) 0.729 -0.84 (-2.15, 0.48) 0.213 
HIV+ only 
 eGFR (mL/min/1.73m2) -0.74 (-1.50, 0.01) 0.055 -0.64 (-1.33, 0.05) 0.069 -0.90 (-1.67, -0.13) 0.023 
Abbreviations: CIMT, Carotid Intima Media Thickness; Cr, Creatinine; CysC, Cystatin C; eGFR, estimated glomerular filtration rate based on CKD-
EPI equations using either Creatinine, Cystatin C, or both 
aIn the overall cohort, the β-coefficients are from a multivariable regression model including eGFR (per 1 mL/min/1.732), HIV status (positive vs. 
negative), and the interaction between eGFR and HIV status on the level of CIMT (in µm). Variables included in all models include age, 
race/ethnicity, sex, smoking status, body mass index, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, total cholesterol, 
triglycerides, systolic and diastolic blood pressures, history of diabetes, and Hepatitis C serostatus.  Similar regression models were then constructed 
to assess the relationships between eGFR and CIMT using just HIV+ participants including several HIV-specific variables such as history of 





Table 2. Relationships between eGFR (using 3 CKD-EPI equations) and Coronary Artery Calcification in HIV-positive and HIV-negative 
Individuals. 
CAC (+/-) 
Cr Model CysC Model Cr-CysC Model 
β (95% CI)a P-value β (95% CI)a P-
value 
β (95% CI)a P-value
Overall cohort 





0.215 0.032 (0.000,8.936) 0.233 







0.197 0.973 (0.927,1.021) 0.268 







0.468 0.997 (0.979,1.015) 0.734 





0.307 1.025 (0.974,1.078) 0.349 
HIV+ only 





0.364 0.996 (0.978,1.015) 0.699 
CAC log10 Agat 
Cr Model CysC Model Cr-CysC Model 
β (95% CI)a 
P-
value 
β (95% CI)a P-value β (95% CI)a P-value
Overall cohort 









   HIV- eGFR 
(mL/min/1.73m2) 
4.18 (-13.83,22.18) 0.650 -8.57 (-27.94,10.79) 0.388 -3.47 (-23.55,16.62) 0.736 
   HIV+ eGFR 
(mL/min/1.73m2) 
3.82 (-4.52,12.15) 0.371 -9.72 (-17.46,-1.97) 0.016 -3.64 (-12.49,5.20) 0.421 
   HIV*eGFR interaction -0.36 (-19.56,18.83) 0.971 -1.14 (-21.29,19.00) 0.912 -0.17 (-21.28,20.93) 0.987 
HIV+ only 





Abbreviations: Cr, Creatinine; CysC, Cystatin C; eGFR, estimated glomerular filtration rate based on CKD-EPI equations using either Creatinine, 
Cystatin C, or both; CAC log Agat, Coronary Artery Calcium log10 Agatson score; CAC(+/-), Coronary Artery Calcium detectable/nondetectable. 
aIn the overall cohort, the β-coefficients are from a multivariable regression model including eGFR (per 1 mL/min/1.732), HIV status (positive vs. 
negative), and the interaction between eGFR and HIV status on the level of CAC (log10 Agatson score or as detectable vs. nondetectable). Variables 
included in all models include age, race/ethnicity, sex, smoking status, body mass index, high density lipoprotein-cholesterol, low density 
lipoprotein-cholesterol, total cholesterol, triglycerides, systolic and diastolic blood pressures, history of diabetes, and Hepatitis C serostatus.  Similar 
regression models were then constructed to assess the relationships between eGFR on CAC using just HIV+ participants including several HIV-
specific variables such as history of antiretroviral use, CD4 cell count and HIV-1 RNA level. 
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